Teduglutide ELISA Kit

Catalog No.

KDB76601

Description

Teduglutide, a glucagon-like peptide 2 (GLP-2) analogue and GLP-2R agonist, consists of 33 amino acids and can be used in short bowel syndrome (SBS) related studies.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

156.25 - 10,000 ng/mL

Sensitivity

99.45 ng/mL

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

Teduglutide, ALX 0600, Gattex, Revestive, TAK, CAS: 197922-42-2

Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study., PMID:40515554

Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome., PMID:40414050

Updates in Intestinal Failure Management., PMID:40364063

Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues., PMID:40363720

Review of cost-effectiveness analysis to study pediatric intestinal failure and transplant., PMID:40264472

Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey., PMID:40229535

Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications., PMID:40219687

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database., PMID:40213702

European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption., PMID:40129317

Corrigendum to "Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey" Clin Nutr 2025 Feb 17:47:54-67., PMID:40117964

GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice., PMID:40114026

Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice., PMID:40097102

European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN: Part 2: Screening, Special Populations, Nutritional Goals, Supportive Care, Primary Care Perspective., PMID:40088199

Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide., PMID:40086997

Survival and parenteral nutrition dependence in patients aged 65 y and older with short bowel syndrome: a retrospective observational cohort study., PMID:40074039

Successful treatment with teduglutide for an adolescent with cerebral palsy accompanied by short bowel syndrome., PMID:40019443

Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey., PMID:39986179

Successful Pregnancy in a Patient with Crohn's Disease and Short Bowel Syndrome: Off Total Parenteral Nutrition and On Teduglutide, a Glucagon-Like Peptide-2 Analog - A Case Report., PMID:39906192

Glucagon-like peptides agonists promote maturation of intestinal organoids derived from neonates with necrotizing enterocolitis., PMID:39828765

Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions., PMID:39788016

Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study., PMID:39689615

Therapeutic interventions targeting enteropathy in severe acute malnutrition modulate systemic and vascular inflammation and epithelial regeneration., PMID:39662176

Novel homozygous nonsense mutation in glucagon-like peptide-2 receptor gene resulting in severe human illness., PMID:39610412

Home Parenteral Support in Chronic Intestinal Failure-First Results from a Pioneer Portuguese Intestinal Failure Center., PMID:39599666

Use of glucagon-like polypeptide 2 analogs for intestinal failure., PMID:39588923

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals., PMID:39519595

Real-world experience with glucagon-like peptide 2 analogues in patients with short bowel syndrome and chronic intestinal failure: Results from an international survey in expert intestinal failure centers., PMID:39489296

Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report., PMID:39439449

Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden., PMID:39412630

The Epidemiology and Clinical Management of Short Bowel Syndrome and Chronic Intestinal Failure in Crohn's Disease in Italy: An IG-IBD Survey., PMID:39408277

Pancreatitis Associated With Teduglutide: A Disproportionality Analysis via the Food and Drug Administration Adverse Event Reporting System (FAERS) Database., PMID:39350843

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database., PMID:39329127

Retrospective review of growth in pediatric intestinal failure after weaning from parenteral nutrition., PMID:39263924

Optimizing peripubertal growth in a child with short bowel syndrome on full oral feeding with glucagon-like peptide 2 analog., PMID:39149188

Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry., PMID:39125394

Achieving Enteral Autonomy in Children with Intestinal Failure Following Inpatient Admission: A Case Series., PMID:39095008

Management of Short Bowel Syndrome With Chronic Intestinal Failure: A Single-Center Experience in Portugal., PMID:39077232

Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease., PMID:39007246

Intestinal adaptation and rehabilitation in adults with short bowel syndrome., PMID:38963563

Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure., PMID:38873891

Cholecystitis following the initiation of glucagon-like peptide-2 analogue for short bowel syndrome: A case report., PMID:38796751

Emerging drugs for the treatment of short bowel syndrome., PMID:38761162

Reversal of Intestinal Failure With Teduglutide in PERCC1-Associated Enteropathy: A Case Report., PMID:38710080

Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study., PMID:38664251

Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis., PMID:38663565

Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial., PMID:38632262

Evaluation of the Effectiveness of Teduglutide Treatment in Patients with Short Bowel Syndrome in Slovakia-Multicenter Real-World Study., PMID:38592065

Teduglutide-induced acute gastric mucosal necrosis in short bowel syndrome with hepatorenal failure: Case report., PMID:38493615

Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis., PMID:38491966

The Czech Home Parenteral Nutrition Registry REDNUP: Comprehensive Analysis of Adult Patients' Data., PMID:38471467

Document Download

Teduglutide ELISA Kit.pdf